Bio-Rad Laboratories stocks have experienced considerable fluctuation, with a notable decrease over the past several years. Despite receiving an average
'Hold' rating from brokerages, the stocks have unfortunately lost 47% of their value. Significant share sales and acquisitions have been noted, including a large sale by
Marathon Asset Management and major investments by
Boston Trust Walden Corp and
Allspring Global Investments Holdings LLC. Bio-Rad's third quarter earnings missed estimates, resulting in stock fall, despite revenues surpassing forecasts. Their Q2 2025 earnings showcased
steady growth despite challenges, an outlook that is reflected in the company's acquisition by major investors. They have also been highlighted for their
low debt despite a stock price drop, making them seem undervalued. Despite these challenges, multiple analysts have boosted their price targets for Bio-Rad, attributing sustainable value to their
steady business and stake in
Sartorius. Additionally, despite recent losses, Bio-Rad suggests a potential for a turnaround narrative due to its undervalued status. They have announced a
$500M share repurchase program, a move that could possibly shift investors' perceptions.
Bio-Rad Laboratories Stocks News Analytics from Tue, 24 Nov 2015 08:00:00 GMT to Sat, 03 Jan 2026 08:20:19 GMT -
Rating -4
- Innovation 5
- Information 6
- Rumor -2
